A recent brief communication in NPJ Primary Care Respiratory Medicine highlights the extensive economic toll of long COVID, estimating an annual global cost of approximately $1 trillion—equivalent to about 1% of worldwide gross domestic product. The assessment draws on multiple studies and reports, evaluating the condition’s effects on healthcare systems, labor productivity, national economies, and overall well-being.
Estimates of long COVID prevalence vary significantly. While conservative figures range from 2% to 7%, a 2024 systematic review of 144 studies suggests a rate of 36%, with higher incidence among hospitalized patients, adults, and women. Even under cautious assumptions, the financial impact remains substantial. One model projects $3.7 trillion in yearly losses, with 59% tied to diminished quality of life and the rest stemming from lost income and increased medical costs.
In the United States, annual wage losses due to long COVID may reach $170 billion, with some analyses indicating even higher figures. Affected individuals often face elevated healthcare expenses. A UK study of 282,080 adults found that median annual healthcare spending for those with long COVID was £705 ($924), notably higher than pre-pandemic levels (£306, or $401) and other comparison groups. Out-of-pocket costs for treatments and insurance copayments add further strain, while reduced work hours or extended unemployment deepen household financial stress. Women, low-income workers, and the uninsured are disproportionately affected.
Beyond measurable costs, the condition carries intangible burdens—social isolation, mental health challenges, and reduced daily functioning—that are difficult to quantify but deeply impactful. The authors emphasize that vaccination plays a protective role, reducing the risk of developing long-term symptoms by about 21% in U.S. adults and 16% globally, underscoring its importance in mitigating long-term socioeconomic consequences.
They also stress the need for improved data collection, citing inconsistent case definitions, lack of biomarkers, and inadequate reporting systems as barriers to accurate assessment. Future research should include long-term cohort studies and detailed analyses of symptom clusters to better understand the economic footprint across different patient profiles. In the absence of comprehensive data, insights from chronic conditions like ME/CFS (myalgic encephalomyelitis and chronic fatigue syndrome) could inform policy and resource planning.
— news from CIDRAP
— News Original —
Long COVID takes $1 trillion global economic toll each year, analysis suggests
A brief communication published last week in NPJ Primary Care Respiratory Medicine outlines the substantial economic burden of long COVID worldwide, estimating that persistent symptoms after COVID infection cost the global economy roughly $1 trillion each year, or roughly 1% of global gross domestic product. n nThe analysis looked at data across numerous studies and reports, analyzing long COVID’s impact on national economies, healthcare systems, labor markets, and quality of life. n nGlobal prevalence estimates of long COVID vary widely. Conservative estimates suggest a range of 2% to 7%, while a systematic review of 144 studies published through 2024 suggests a prevalence of 36%, with higher rates reported in hospitalized patients, adults, and women. n nEven using more conservative estimates, the economic footprint of long COVID is “material and persistent,” write the authors. One economic model suggests $3.7 trillion in annual losses associated with long COVID, with 59% attributed to decreases in quality of life and the remaining losses attributed to reduced earnings and increased medical expenses. n nIn the United States alone, analyses suggest that long COVID may be responsible for $170 billion in annual lost wages, with some estimates ranging even higher. n nEconomic, social, and psychological impacts n nPatients with long COVID often require more medical care, which comes at considerable personal expense. In a large study of 282,080 adults in the United Kingdom, annual median healthcare expenditures were £705 ($924), “substantially higher than observed in pre-long COVID (£294 [$385]), COVID-19 only (£447 [$586]), pre-pandemic (£306 [$401]), and contemporary non–COVID-19 (£350 [$459]) cohorts.” n nMany patients also incur out-of-pocket medical expenses for fully self-funded treatments and insurance copayments. Reduced work hours and prolonged unemployment can also add to families’ economic hardship. Women, lower-income workers, and people without health insurance are hit even harder. n nIntangible impacts such as reduced social participation, psychological distress, and diminished quality of life are harder to quantify but no less real. “These impacts represent a profound impact on societal well-being,” write the authors. n nEmerging evidence suggests that the economic implications of long COVID are profound and multifaceted. n nThe paper highlights emerging evidence that COVID-19 vaccination substantially reduces the prevalence of long COVID, lowering risk by approximately 21% in US adults and 16% globally—an important consideration for strategies aimed at minimizing long-term economic fallout. n n”Emerging evidence suggests that the economic implications of long COVID are profound and multifaceted, necessitating a comprehensive understanding to inform global policy and resource allocation,” the authors conclude. n nUnderstanding full economic burden requires more research n nThe authors highlight the lack of standardized case definitions, evidence-based biomarkers, and reporting mechanisms for long COVID as factors that hinder accurate data collection about the economic impacts of long COVID. n nDespite increased awareness, understanding the economic burden of long COVID will require more research, write the authors, citing a need for comprehensive longitudinal studies to track the economic impact on individuals and healthcare systems over time, more longer-term cohort studies (most existing studies are cross-sectional or short-to-medium term), and more granular analyses to better understand the burden associated with different long COVID phenotypes (observable characteristics) and symptom clusters. n nIn the meantime, the authors advocate learning from other chronic conditions and post-viral syndromes. “The economic modelling and management strategies for other chronic post-viral syndromes or debilitating conditions (e.g., ME/CFS [myalgic encephalomyelitis and chronic fatigue syndrome] can provide valuable insights for projecting and mitigating the long-term economic burden of long COVID.”